The metabolic brain pattern of young subjects given scopolamine

Robert M. Cohen, Michael Gross, William E. Semple, Thomas E Nordahl, Trey Sunderland

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The effect of an intravenous dose of 0.5 mg of scopolamine on the functional brain activity of normal subjects performing auditory discrimination (CPT) was determined in two independent positron emission tomography studies with [18F] 2-fluoro-deoxyglucose. In the first preliminary study, the most significant effect found was a reduction in the functional activity of the thalamus. In the second "hypothesis-testing" study, an equally prominent effect on thalamic functional activity was seen. Because the second study was performed on a high-resolution scanner with improved methodology, we re-examined scopolamine's effects on those brain regions established as determinants of CPT. Of the regions affected, the reduction in cingulate and the increase in basal ganglia metabolic rates were the most notable. We concluded that scopolamine's effects on the functions of thalamic, cingulate and basal ganglia are the likely causes of scopolamine's well-described attention-altering properties. Alterations in these same brain structures could be responsible for scopolamine's effects on other cognitive functions, e.g., memory. Alternatively, scopolamine's effects on other brain structures such as the hippocampus and frontal cortex could underlie scopolamine's effects on these other cognitive functions. Studies of scopolamine's regional metabolic effects in subjects performing these other cognitive tasks at more than a single dose and at more than one post-drug time are needed to discriminate between these two possibilities.

Original languageEnglish (US)
Pages (from-to)133-143
Number of pages11
JournalExperimental Brain Research
Volume100
Issue number1
DOIs
StatePublished - Jul 1994
Externally publishedYes

Fingerprint

Scopolamine Hydrobromide
Brain
Basal Ganglia
Cognition
Basal Metabolism
Deoxyglucose
Frontal Lobe
Thalamus
Positron-Emission Tomography
Hippocampus
Pharmaceutical Preparations

Keywords

  • Attention
  • Basal ganglia
  • Human
  • Positron emission tomography
  • Thalamus

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The metabolic brain pattern of young subjects given scopolamine. / Cohen, Robert M.; Gross, Michael; Semple, William E.; Nordahl, Thomas E; Sunderland, Trey.

In: Experimental Brain Research, Vol. 100, No. 1, 07.1994, p. 133-143.

Research output: Contribution to journalArticle

Cohen, Robert M. ; Gross, Michael ; Semple, William E. ; Nordahl, Thomas E ; Sunderland, Trey. / The metabolic brain pattern of young subjects given scopolamine. In: Experimental Brain Research. 1994 ; Vol. 100, No. 1. pp. 133-143.
@article{c8b81111640043179704bd723e26a418,
title = "The metabolic brain pattern of young subjects given scopolamine",
abstract = "The effect of an intravenous dose of 0.5 mg of scopolamine on the functional brain activity of normal subjects performing auditory discrimination (CPT) was determined in two independent positron emission tomography studies with [18F] 2-fluoro-deoxyglucose. In the first preliminary study, the most significant effect found was a reduction in the functional activity of the thalamus. In the second {"}hypothesis-testing{"} study, an equally prominent effect on thalamic functional activity was seen. Because the second study was performed on a high-resolution scanner with improved methodology, we re-examined scopolamine's effects on those brain regions established as determinants of CPT. Of the regions affected, the reduction in cingulate and the increase in basal ganglia metabolic rates were the most notable. We concluded that scopolamine's effects on the functions of thalamic, cingulate and basal ganglia are the likely causes of scopolamine's well-described attention-altering properties. Alterations in these same brain structures could be responsible for scopolamine's effects on other cognitive functions, e.g., memory. Alternatively, scopolamine's effects on other brain structures such as the hippocampus and frontal cortex could underlie scopolamine's effects on these other cognitive functions. Studies of scopolamine's regional metabolic effects in subjects performing these other cognitive tasks at more than a single dose and at more than one post-drug time are needed to discriminate between these two possibilities.",
keywords = "Attention, Basal ganglia, Human, Positron emission tomography, Thalamus",
author = "Cohen, {Robert M.} and Michael Gross and Semple, {William E.} and Nordahl, {Thomas E} and Trey Sunderland",
year = "1994",
month = "7",
doi = "10.1007/BF00227285",
language = "English (US)",
volume = "100",
pages = "133--143",
journal = "Experimental Brain Research",
issn = "0014-4819",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The metabolic brain pattern of young subjects given scopolamine

AU - Cohen, Robert M.

AU - Gross, Michael

AU - Semple, William E.

AU - Nordahl, Thomas E

AU - Sunderland, Trey

PY - 1994/7

Y1 - 1994/7

N2 - The effect of an intravenous dose of 0.5 mg of scopolamine on the functional brain activity of normal subjects performing auditory discrimination (CPT) was determined in two independent positron emission tomography studies with [18F] 2-fluoro-deoxyglucose. In the first preliminary study, the most significant effect found was a reduction in the functional activity of the thalamus. In the second "hypothesis-testing" study, an equally prominent effect on thalamic functional activity was seen. Because the second study was performed on a high-resolution scanner with improved methodology, we re-examined scopolamine's effects on those brain regions established as determinants of CPT. Of the regions affected, the reduction in cingulate and the increase in basal ganglia metabolic rates were the most notable. We concluded that scopolamine's effects on the functions of thalamic, cingulate and basal ganglia are the likely causes of scopolamine's well-described attention-altering properties. Alterations in these same brain structures could be responsible for scopolamine's effects on other cognitive functions, e.g., memory. Alternatively, scopolamine's effects on other brain structures such as the hippocampus and frontal cortex could underlie scopolamine's effects on these other cognitive functions. Studies of scopolamine's regional metabolic effects in subjects performing these other cognitive tasks at more than a single dose and at more than one post-drug time are needed to discriminate between these two possibilities.

AB - The effect of an intravenous dose of 0.5 mg of scopolamine on the functional brain activity of normal subjects performing auditory discrimination (CPT) was determined in two independent positron emission tomography studies with [18F] 2-fluoro-deoxyglucose. In the first preliminary study, the most significant effect found was a reduction in the functional activity of the thalamus. In the second "hypothesis-testing" study, an equally prominent effect on thalamic functional activity was seen. Because the second study was performed on a high-resolution scanner with improved methodology, we re-examined scopolamine's effects on those brain regions established as determinants of CPT. Of the regions affected, the reduction in cingulate and the increase in basal ganglia metabolic rates were the most notable. We concluded that scopolamine's effects on the functions of thalamic, cingulate and basal ganglia are the likely causes of scopolamine's well-described attention-altering properties. Alterations in these same brain structures could be responsible for scopolamine's effects on other cognitive functions, e.g., memory. Alternatively, scopolamine's effects on other brain structures such as the hippocampus and frontal cortex could underlie scopolamine's effects on these other cognitive functions. Studies of scopolamine's regional metabolic effects in subjects performing these other cognitive tasks at more than a single dose and at more than one post-drug time are needed to discriminate between these two possibilities.

KW - Attention

KW - Basal ganglia

KW - Human

KW - Positron emission tomography

KW - Thalamus

UR - http://www.scopus.com/inward/record.url?scp=0027935108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027935108&partnerID=8YFLogxK

U2 - 10.1007/BF00227285

DO - 10.1007/BF00227285

M3 - Article

C2 - 7813641

AN - SCOPUS:0027935108

VL - 100

SP - 133

EP - 143

JO - Experimental Brain Research

JF - Experimental Brain Research

SN - 0014-4819

IS - 1

ER -